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A ge-related macular degeneration (AMD) is the third leading cause of vision loss worldwide and the most common form of legal blindness in the elderly. 1 Millions of individuals who are older than 50 years in Europe and North America have AMD, and it is estimated that more than 300,000 new cases are diagnosed annually. 2, 3 During aging, focal deposits of debris can accumulate below the retinal pigment epithelium (RPE) that are recognized in an eye examination as drusen. Clinicians have long recognized that drusen in the macula are early stages in the AMD disease process. Drusen in the macula and the size and area covered by these deposits are considered risk indicators for later development of the blinding end-stage forms of AMD. 4 -6 Geographic atrophy is the end-stage of the dry form, characterized by the slow, progressive loss of the RPE. 7 Photoreceptor function is lost in regions subtended by RPE atrophy. When geographic atrophy involves the RPE below the fovea, foveal photoreceptors lose function and degenerate, causing foveal blindness. Choroidal neovascularization characterizes the wet form of AMD. When new blood vessels growing from the choroid break through Bruch's membrane and the RPE, they can hemorrhage, causing a pool of blood to accumulate between the RPE and foveal photoreceptors resulting in acute loss of vision. 4, 5 Initial studies on AMD by my colleagues and myself focused on understanding the composition and distribution of drusen proteins. 8 -13 More than 120 different proteins were identified in isolated drusen. Several laboratories have made significant contributions to the understanding of drusen composition in recent years, and a consistent finding is that many complement pathway proteins are present in drusen, suggesting that inflammation is a part of the AMD disease process. 9,14 -18 Epidemiologic studies of elderly twins pointed to the likelihood that genetic factors have a role in AMD. 19 -22 Recent reports indicate that mutations/polymorphisms in genes coding for the alternative complement pathway regulator (factor H and factor H-related proteins) and complement pathway proteins (complement component C2, C3, and factor B) are present in more than 50% of patients with AMD. Collectively, these studies strongly indicate that AMD has a genetic component and that inflammation plays an important role in the pathology of AMD. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The complement system is critical for inflammation and immune responses. Soluble complement proteins are present in the blood in precursor forms and require activation to achieve their specific physiological roles. Activated complement has diverse functions, including the initiation of inflammation, recruitment of leukocytes, clearance of immune complexes, neutralization of pathogens, regulation of antibody responses, and disruption of cell membranes. The complement cascade can be activated by three initiating pathways. The classic activation pathway depends on assembly of complement factors at sites of antigen-antibody complexes. The lectin pathway is initiated by mannan-binding lectin on pathogen surfaces. Activation of the alternative pathway is triggered by the spontaneous hydrolysis ("tickover") of the third complement component (C3), allowing binding to factor B and factor D. Regardless of the pathway, activation leads to the cleavage of C3, which generates the smaller, proinflammatory C3a fragment and the larger C3b fragment. C3b interacts with other activated proteins to form the important convertases required for the terminal part of the complement cascade that culminates in the assembly of the C5b-C9 membrane attack complex (MAC) and cell lysis. Most of the complement pathway proteins are found in drusen and sub-RPE deposits, including C5b-9, indicating that the MAC has been assembled. 9,14 -18 Although the data indicating that the complement pathway is involved in AMD are unequivocal, it is not known how systemic changes caused by polymorphisms in complement pathway genes could result in a localized disease in the outer retina. I reasoned that the highly targeted lesions of the RPE and photoreceptors of the macula must be directed by a specific inflammatory signal generated and released by these tissues. An early hint of a potential inflammatory signal that could come from these tissues was the finding that many proteins found in drusen were not normal (native), but were covalently cross-linked into high-molecular-weight aggregates, modifications that can be caused by reactive lipid and carbohydrate oxidation products. Many of the drusen proteins were covalently modified with adducts, including advanced glycation end products and pyrrole adducts generated from the oxidative damage of docosahexaenoic acid (DHA).
9 Carboxyethylpyrrole (CEP) adducts were identified on albumin, pyruvate kinase, glutathione S-transferase, and several other drusen proteins. 8 In addition, it was found that these CEP adducts were more prevalent in AMD donor eyes than in RPE/Bruch's membrane/ choroid tissues from normal age-matched donor tissue. 9 Plasma samples from patients with AMD contained 40% higher levels of CEP-adducted protein and autoantibodies to CEP than were present in plasma of healthy age-matched donors without AMD. 33 The presence of these oxidation fragments derived from DHA are of particular interest because of the long-recognized association of AMD with oxidative damage. 34 -37 The findings that smoking is a risk factor for AMD 34, 38, 39 and antioxidant vitamins and zinc reduce the risk of vision loss in AMD also support the notion that oxidative damage plays a fundamental role in this disease. 40 Could this CEP adduct, derived specifically from oxidative damage to DHA, be the inflammatory signal from the outer retina that initiates AMD?
DHA is the most oxidizable fatty acid in the body and is highly concentrated in the membrane-rich photoreceptor outer segment and in the RPE. 41, 42 High levels of oxygen delivered to these tissues by the choriocapillaris, coupled with the intense focus of environmental light on the macula provides a highly permissive environment for the generation of reactive oxygen that can damage DHA. Once generated, these oxidation fragments condense with amino acid groups in proteins (i.e., Cys, Lys, and His) to generate Michael, Schiff-base, and pyrrole adducts. Although DHA is only one of many sources of lipid-derived protein adducts, its extremely high concentration in the outer retina makes this fatty acid a likely source of adducts in this tissue. Other polyunsaturated fatty acids, their phospholipids, and cholesterol ester derivatives can also generate a complex mixture of oxidation products that are capable of reacting with protein. Pyrrole adducts are an important class of lipid-derived protein modifications that include CEP from DHA; carboxypropylpyrrole (CPP) from arachidonic acid; and carboxyheptylpyrrole (CHP) from linolenic acid. 43 Interest was focused on CEP because of the following considerations: (1) CEP is a novel adduct that is generated only by oxidative damage to DHA; (2) DHA, although present in every cell in the body, is more concentrated in the outer retina in photoreceptors and RPE than in any other cell in the body; (3) high oxygen levels and light in the outer retina provide a permissive environment for oxidative damage to DHA; (4) CEP adducts are more abundant in the outer retina in AMD donor eyes than in normal age-matched control eyes; and (5) CEP adducts and autoantibodies to CEP are more abundant in the serum of patients with AMD than in normal age-matched control subjects. With these considerations, a hypothesis was developed as to the identity of the inflammatory signal generated in the outer retina and why individuals with mutations/polymorphisms in complement pathway genes might be more susceptible to developing AMD: CEP adducts are slowly generated during aging in the outer retina. Some of the CEP precursor fragments or CEP-adducted proteins are deposited in Bruch's membrane and in the debris accumulating below the RPE. CEP adducts are antigenic, and antibodies against CEP are produced by the immune system. In individuals with normal protective mechanisms against oxidative damage, only small amounts of these adducts are generated. In contrast, more adducts are likely to be produced in individuals who have compromised protection against oxidative damage (e.g., smoking, superoxide dismutase dysfunction, etc.). When an inflammatory response is mounted against CEP adducts in an individual with an altered ability to regulate the complement activation, the possibility of end-stage AMD is greatly enhanced.
To test some of the ideas in this hypothesis, a series of immunization experiments in normal mice was set up to determine whether CEP adducts may be an inflammatory signal generated in the outer retina that leads to complement-mediated disease during aging. 44 Although the photoreceptors are behind the blood retinal barrier, and apical border of the RPE is also inside the blood retinal barrier, the basolateral border interacting with Bruch's membrane is not. It is likely that much of the CEP adducts generated by oxidative damage in photoreceptors and RPE are released slowly during aging for interaction with the immune system. By systemically immunizing mice with a CEP-adducted protein I expected to sensitize mice to endogenously generated CEP. I predicted that as these sensitized mice aged, endogenous CEP adducts generated preferentially by these cells would result in a more aggressive immune response and some pathologic features similar to AMD may appear.
As a carrier for the CEP hapten I used mouse serum albumin (MSA) and chemically modified it to generate CEP-MSA. 45 Aliquots of CEP-MSA were emulsified in complete Freund's adjuvant (CFA) and C57BL/6 mice were immunized after conventional immunization procedures. 46 Two immunization protocols were followed: a "short-term" protocol with three immunizations during a 3-month period; and a "long-term" protocol with a single immunization and maintenance of the mice for 12 to 14 months. Spleen, lymph nodes, eyes, kidney, brain, testes, and blood were sampled for immunologic and/or histologic analysis after euthanatization. Control immunizations used were nonadducted MSA or complete Freund's adjuvant (CFA) applied in the same sequence as CEP-MSA.
The sera from these mice were evaluated for CEP antibodies by ELISA and it was found that circulating anti-CEP antibody levels were six to eight times higher in the CEP-MSA immunized mice than in the naïve and control mice immunized with MSA or CFA. 44 For pathology, eyes taken at the end of the experimental period were prepared for detailed microscopic analysis by procedures described previously. 47 In eyes from the CEP-MSA mice in the short-term immunization protocol, dramatic lesions were present that primarily involved the RPE (Fig. 1) . These changes included vesiculation, hypertrophy, pyknosis, and lysis of RPE cells. In some areas, only single RPE cells were involved, whereas in other areas stretches of the RPE over 2 to 10 cell expanses showed these pathologic changes. More extensive degeneration was occasionally observed involving areas where the entire RPE was absent, producing focal areas similar to that observed when the RPE is lost in geographic atrophy. Photoreceptors under areas of RPE atrophy remained but were highly edematous and swollen. The amount of degeneration in these experiments was scored by counting the number of individual lesions in each of three or four sections examined throughout the retina from the dorsal to the ventral ciliary margin in each eye. When the degree of pathology to the antibody titer in these animals was compared, a close correlation between the CEP-antibody titer and the severity of outer retina disease was noted. 44 Is the complement system involved in the generation of the disease observed in the RPE? Complement component 3 (C3) is a key complement protein that must be processed for complement activation through classic, lectin, or alternative arms. 48 To determine whether complement deposition occurred in these CEP-MSA immunized mice, immunohistochemical analysis was performed to localize of C3d, a degradation fragment of C3 that is deposited in tissues where complement is activated. Frozen sections were analyzed from CEP-MSA immunized and control mice after staining with an anti-C3d antibody. A strong C3d signal was present in Bruch's membrane below the RPE in the mice receiving CEP-MSA immunization (Fig. 2a) , and except for minor fluorescence occasionally seen in mice immunized with the nonadducted MSA (Fig.  2b) , the controls were free of C3d immunoreactivity (Fig. 2c .) It is clear from these data that complement is activated along the basal surface of the RPE after CEP-MSA immunization, suggesting that the complement pathway may be fundamentally involved in generation of the pathologic changes observed in the adjacent RPE. 44 Histology of the outer retina in mice immunized with CEP-MSA in the long-term protocol and examined 12 to 14 months later revealed an accumulation of sub-RPE deposits. 44 Although these deposits are evident at the resolution of light microscopy, their structural features are more striking when viewed with electron microscopy. Figure 3 presents a comparison of the RPE/Bruch's membrane/choriocapillaris interface from agematched naive mouse (Fig. 3a) and a mouse immunized with CEP-MSA 1 year before death. In the CEP-MSA immunized animal, an extensive buildup of flocculent material is present between the greatly expanded basal infoldings of the RPE. Some of this debris shows distinct banding patterns with a periodicity characteristic of "long-spaced collagen." Bruch's membrane is also greatly swollen. Choroidal neovascularization was not observed in any of the animals, suggesting that the disease generated is a model for the dry-type of AMD. Sub-RPE material did not develop in control subjects, although increased thickening of RPE basal infoldings was evident with aging.
These data establish the proof of concept that CEP-MSA immunized C57BL/6 mice develop immune responses to CEP-MSA immunization that result in targeted RPE changes in the outer retina. The correlation between the level of anti-CEP antibody titer and the degree of disease suggests that activation may be mediated through the classic arm of the complement activation pathway, leading to the deposition and processing of C3 in Bruch's membrane. The focal loss of RPE observed resembles geographic atrophy, one of the end-stage conditions in human AMD. Although it is unlikely that CEP is the only No immunofluorescence is present in Bruch's membrane in this preparation from a mouse receiving only the adjuvant. Each section was also stained with propidium iodide, but only a small amount of nuclear fluorescence is evident because of the quenching by the highly melanized RPE and choroid in C57/Bl mice used in these studies. Each micrograph shown is photographed and imaged at the same magnification. Bar, 10 m. inflammatory signal involved in the initiation of an immune response leading to AMD, it is clear from these studies that when this hapten is presented to normal mice in the manner described, it is sufficient to initiate a targeted attack on the RPE. This is the first demonstration that a hapten generated by the oxidative damage to DHA 45 that is present in drusen of AMD donor eyes 9 and plasma from patients with AMD 33 is sufficient to produce AMD-like lesions in mice.
From the outcome of these studies, a new working model for AMD generation has emerged that integrates the idea of a tissue-specific inflammatory signal with the recent findings that polymorphisms/mutations in complement pathway genes are linked to AMD. This model is built on the concept of an interplay between the rate of inflammatory signal generation in the outer retina, the immune systems response to the inflammatory signal and the regulation of complement pathway activation in the tissue where the inflammatory signal is generated. In Figure 4a , the left ordinate indicates the progressive increase in oxidative damage and autoantibody production during aging, as shown on a double-ordinate plot. The right ordinate reflects the efficiency of complement regulation, which establishes a disease threshold (shown as the shaded background). The conditions depicted in Figure 4a reflect the interaction of these two processes in a normal individual without AMD. Although the inflammatory signal generated in the outer retina and autoantibody levels increase during aging, the level of these signals do not reach the disease threshold during the lifetime of the individual. In Figure 4b , the rate of inflammatory signal from the outer retina and autoantibody levels progress at the same rate as in Figure 4a , but polymorphisms/mutations in complement genes lower the disease threshold and allow these two lines to intersect and AMD to be manifest. For simplicity, Figure 4b depicts complement polymorphisms as having an effect on reducing the disease threshold. Several complement polymorphisms are described that reduce the risk for AMD, which in this model would elevate the disease threshold. In Figure 4c , changes in the systemic protection in oxidative damage, or environmental conditions that are permissive of oxidative damage result in an increase in the rate of inflammatory signal generation, changing the slope of the dashed line and allowing an early intersect with the disease threshold. Changes in the right and left ordinates should be expected to vary independently. Higher rates of inflammatory signal generation coupled with a lower disease threshold would result in an early onset of AMD. Conversely, a lower rate of inflammatory signal generation in an individual with efficient complement regulation would be reflected in the graph in Figure 4a . Figure  4d shows how the immunization of the mouse with CEP fits with this AMD disease model. Normally, CEP would be generated in the outer retina and slowly evoke an immune response that would not reach the disease threshold (similar to that shown in Fig. 4a ). Systemic immunization in the mouse changes the slope of the dashed line (through the generation of the CEP antibody), which rapidly reaches the disease threshold. Complement mediated attack is directed toward the RPE in the outer retina because of the specific generation of CEP adducts in this tissue.
This mouse model for AMD provides a new resource for understanding the early interaction of inflammatory signals originating in the outer retina with the immune system that initiate AMD. Progression of this outer retinal pathology and the severity of these lesions can also be studied in mice that are missing key complement pathway genes, as a means of evaluating the relative importance of the different complement activation arms in AMD. Because the model is based on an inflammatory signal discovered in AMD eye tissues and replicates several features of AMD, it may also become a useful preclinical platform for testing the efficacy of drugs that are designed to prevent or modify the rate of pathologic progression.
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